{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:29:33Z","timestamp":1776371373760,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2005,6,23]],"date-time":"2005-06-23T00:00:00Z","timestamp":1119484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1007\/s00228-005-0901-1","type":"journal-article","created":{"date-parts":[[2005,6,27]],"date-time":"2005-06-27T14:08:46Z","timestamp":1119881326000},"page":"375-379","source":"Crossref","is-referenced-by-count":38,"title":["Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection"],"prefix":"10.1007","volume":"61","author":[{"given":"Barbara","family":"Gawro\u0144ska-Szklarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Wrze\u015bniewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Starzy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Safranow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Ferenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Dro\u017adzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,6,23]]},"reference":[{"key":"901_CR1","unstructured":"International Agency for Research on Cancer, World Health Organization (1994) Infection with Helicobacter pylori. In: Schistosomes, liver flukes and Helicobacter pylori. IARC, Lyon, pp 177\u2013202"},{"key":"901_CR2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.1996.03530320046033","volume":"275","author":"AH Soll","year":"1996","unstructured":"Soll AH (1996) Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [review]. JAMA 275:622\u2013629","journal-title":"JAMA"},{"key":"901_CR3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2036.2002.01169.x","volume":"16","author":"P Malfertheiner","year":"2002","unstructured":"Malfertheiner P, Megraund F, Morain CO et al (2002) Current concepts in the management of Helicobacter pylori infection. The Maastricht 2\u20132000 Consensus Report. Alim Pharmacol Ther 16:167\u2013180","journal-title":"Alim Pharmacol Ther"},{"key":"901_CR4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1365-2036.2001.00974.x","volume":"15","author":"MJR Janssen","year":"2001","unstructured":"Janssen MJR, Van Oijen AHAM, Verbeek ALM et al (2001) A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor\/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitromidazole. Aliment Pharmacol Ther 15:613\u2013624","journal-title":"Aliment Pharmacol Ther"},{"key":"901_CR5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2000.00788.x","volume":"14","author":"CA Stedman","year":"2000","unstructured":"Stedman CA, Barclay ML (2000) Review article: comparison of pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963\u2013978","journal-title":"Aliment Pharmacol Ther"},{"key":"901_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","volume":"39","author":"FP Guengerich","year":"1999","unstructured":"Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1\u201317","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"901_CR7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","volume":"61","author":"PJ Wedlund","year":"2000","unstructured":"Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174\u2013183","journal-title":"Pharmacology"},{"key":"901_CR8","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1572-0241.2003.07427.x","volume":"98","author":"A Sapone","year":"2003","unstructured":"Sapone A, Vaira D, Trespidi S et al (2003) The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. Am J Gastroenterol 98:1010\u20131015","journal-title":"Am J Gastroenterol"},{"key":"901_CR9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","volume":"364","author":"Ch Pauli-Magnus","year":"2001","unstructured":"Pauli-Magnus Ch, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg\u2019s. Arch Pharmacol 364:551\u2013557","journal-title":"Arch Pharmacol"},{"key":"901_CR10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","volume":"62","author":"MM Gottesman","year":"1993","unstructured":"Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62:385\u2013427","journal-title":"Ann Rev Biochem"},{"key":"901_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0009-9236(98)90030-3","volume":"64","author":"H Wakasungi","year":"1998","unstructured":"Wakasungi H, Yano I, Ito T et al (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 64:123\u2013128","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1440-1681.2000.03308.x","volume":"27","author":"L Wang","year":"2000","unstructured":"Wang L, Kitaichi K, Hui CS et al (2000) Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 27:587\u2013593","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"901_CR13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1023\/A:1007570517183","volume":"17","author":"WL Chiou","year":"2000","unstructured":"Chiou WL, Chung SM, Wu TC (2000) Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903\u2013905","journal-title":"Pharm Res"},{"key":"901_CR14","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473\u20133478","journal-title":"Proc Natl Acad Sci USA"},{"key":"901_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169\u2013174","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1067\/mcp.2002.127739","volume":"72","author":"W Siegmund","year":"2002","unstructured":"Siegmund W, Ludwig K, Giessmann T et al (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572\u2013583","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-022X(92)90014-2","volume":"25","author":"CE Haas","year":"1992","unstructured":"Haas CE, Lahiri DK, Bye S, Nurnberger JI Jr (1992) A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples that do nine other methods tested. J Biochem Biophys Met 25:193\u2013205","journal-title":"J Biochem Biophys Met"},{"key":"901_CR18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0076-6879(96)72025-6","volume":"272","author":"JA Goldstein","year":"1996","unstructured":"Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210\u2013217","journal-title":"Methods Enzymol"},{"key":"901_CR19","first-page":"594","volume":"46","author":"SM De Morais","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J et al (1994) Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594\u2013598","journal-title":"Mol Pharmacol"},{"key":"901_CR20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003088-199529030-00005","volume":"29","author":"L Bertilsson","year":"1995","unstructured":"Bertilsson L (1995) Geographical\/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 29:192\u2013209","journal-title":"Clin Pharmacokinet"},{"key":"901_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","volume":"7","author":"JA Goldstein","year":"1997","unstructured":"Goldstein JA, Ishizaki T, Chiba K et al (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American Black populations. Pharmacogenetics 7:59\u201364","journal-title":"Pharmacogenetics"},{"key":"901_CR22","first-page":"203","volume":"69","author":"UA Meyer","year":"1996","unstructured":"Meyer UA (1996) Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med 69:203\u2013209","journal-title":"Yale J Biol Med"},{"key":"901_CR23","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00042737-199610001-00005","volume":"8","author":"UA Meyer","year":"1996","unstructured":"Meyer UA (1996) Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 8:S21\u2013S25","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"901_CR24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1067\/mcp.2001.119721","volume":"70","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Xiao F et al (2001) Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484\u2013492","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1067\/mcp.2001.113959","volume":"69","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Takashima M et al (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin and clarithromycin. Clin Pharmacol Ther 69:158\u2013168","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1067\/mcp.2002.127637","volume":"72","author":"T Furuta","year":"2002","unstructured":"Furuta T, Shirai N, Watanabe F et al (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453\u2013460","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.2003.01804.x","volume":"18","author":"T Shimatani","year":"2003","unstructured":"Shimatani T, Inoue M, Kuroiva T et al (2003) Effect of omeprazole 10\u00a0mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20\u00a0mg and lafutidine 20\u00a0mg, a new H2-receptor antagonist. Aliment Pharmacol Ther 18:1149\u20131157","journal-title":"Aliment Pharmacol Ther"},{"key":"901_CR28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0009-9236(99)70017-2","volume":"66","author":"Y Tanigawara","year":"1999","unstructured":"Tanigawara Y, Aoyama N, Kita T et al (1999) CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 66:528\u2013534","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1067\/mcp.2000.106826","volume":"67","author":"T Furuta","year":"2000","unstructured":"Furuta T, Takashima M, Shirai N et al (2000) Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 67:684\u2013689","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2036.2003.01406.x","volume":"17","author":"H Kawabata","year":"2003","unstructured":"Kawabata H, Habu Y, Tomioka H et al (2003) Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 17:259\u2013264","journal-title":"Aliment Pharmacol Ther"},{"key":"901_CR31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1440-1746.2002.02790.x","volume":"17","author":"T Inaba","year":"2002","unstructured":"Inaba T, Mizuno M, Kawai K et al (2002) Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 17:748\u2013753","journal-title":"J Gastroenterol Hepatol"},{"key":"901_CR32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1248\/bpb.25.923","volume":"25","author":"N Aoyama","year":"2002","unstructured":"Aoyama N et al (2002) Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-it Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull 25:923\u2013927","journal-title":"Biol Pharm Bull"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0901-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-005-0901-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0901-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:22Z","timestamp":1558702282000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-005-0901-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,23]]},"references-count":32,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s00228-005-0901-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,23]]}}}